Garo H. Armen Buys 100,000 Shares of Agenus Inc. (AGEN) Stock
Agenus Inc. (NASDAQ:AGEN) CEO Garo H. Armen acquired 100,000 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The stock was purchased at an average price of $3.55 per share, with a total value of $355,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Agenus Inc. (NASDAQ:AGEN) traded up 2.25% during mid-day trading on Tuesday, reaching $3.63. 1,107,445 shares of the company’s stock traded hands. The company’s 50 day moving average is $4.31 and its 200 day moving average is $3.97. The company’s market cap is $361.95 million. Agenus Inc. has a 12-month low of $3.20 and a 12-month high of $5.91.
Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.04. The business had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $6.66 million. The business’s quarterly revenue was down 36.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.33) earnings per share. On average, analysts predict that Agenus Inc. will post ($1.13) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/31/garo-h-armen-buys-100000-shares-of-agenus-inc-agen-stock.html.
Large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Agenus by 5.2% during the second quarter. Vanguard Group Inc. now owns 3,530,585 shares of the biotechnology company’s stock worth $13,805,000 after purchasing an additional 174,162 shares during the period. Northern Trust Corp raised its stake in Agenus by 4.1% during the second quarter. Northern Trust Corp now owns 941,631 shares of the biotechnology company’s stock worth $3,682,000 after purchasing an additional 37,239 shares during the period. Goldman Sachs Group Inc. raised its stake in Agenus by 3,447.2% during the first quarter. Goldman Sachs Group Inc. now owns 673,333 shares of the biotechnology company’s stock worth $2,539,000 after purchasing an additional 654,351 shares during the period. Bank of New York Mellon Corp raised its stake in Agenus by 38.1% during the first quarter. Bank of New York Mellon Corp now owns 560,799 shares of the biotechnology company’s stock worth $2,114,000 after purchasing an additional 154,715 shares during the period. Finally, Geode Capital Management LLC raised its stake in Agenus by 5.8% during the first quarter. Geode Capital Management LLC now owns 554,572 shares of the biotechnology company’s stock worth $2,090,000 after purchasing an additional 30,265 shares during the period. 39.55% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms recently weighed in on AGEN. Zacks Investment Research upgraded shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Wednesday, July 5th. ValuEngine cut shares of Agenus from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 8th. BidaskClub upgraded shares of Agenus from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. Finally, Jefferies Group LLC restated a “buy” rating and set a $7.00 target price on shares of Agenus in a research note on Friday, August 4th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Agenus presently has a consensus rating of “Hold” and a consensus target price of $5.81.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.